Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma

Investigational New Drugs

Volumn 33, Issue 1, 2015, Pages 247-253

  Schiff, David ^a   Kesari, Santosh ^b   De Groot, John ^c   Mikkelsen, Tom ^d   Drappatz, Jan ^b   Coyle, Thomas ^e   Fichtel, Lisa ^f   Silver, Bruce ^g   Walters, Ian ^h   Reardon, David ⁱ  

^a UNIVERSITY OF VIRGINIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e STATE UNIVERSITY OF NEW YORK   (United States)

^f TEXAS ONCOLOGY   (United States)

^g Adnexus A BMS R and D Co   (United States)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ DUKE UNIVERSITY   (United States)

Author keywords

Adnectin; Anti angiogenic therapy; Glioblastoma; Irinotecan; VEGF receptor

Indexed keywords

FIBRONECTIN; IRINOTECAN; PEGDINETANIB; ANTINEOPLASTIC AGENT; CT-322; GLUCURONOSYLTRANSFERASE; PEPTIDE FRAGMENT; PROTEIN KINASE INHIBITOR; UGT1A1 ENZYME; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BRAIN HEMORRHAGE; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; FATIGUE; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NULL HYPOTHESIS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VEIN THROMBOSIS; AGED; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FIBRONECTINS; GLIOBLASTOMA; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84925543213     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0186-2     Document Type: Article

References (19)

1. Ostrom QT, Gittleman H, Farah P et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15(Suppl 2):ii1-ii56
2. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 14(Suppl 5):v1-v49
3. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996
4. Vredenburgh JJ, Desjardins A, Herndon JE II et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722-4729
5. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740
6. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740-745
7. Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1):83-95
8. Gomez-Manzano C, Holash J, Fueyo J et al (2008) VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 10(6):940-945
9. Tolcher AW, Sweeney CJ, Papadopoulos K et al (2011) Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 17(2):363-371
10. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572-2578
11. Weidle UH, Auer J, Brinkmann U, Georges G, Tiefenthaler G (2013) The emerging role of new protein scaffold-based agents for treatment of cancer. Cancer Genomics Proteomics 10(4):155-168
12. Mamluk R, Carvajal IM, Morse BA et al (2010) Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs 2(2):199-208
13. Letarte N, Bressler LR, Villano JL (2013) Bevacizumab and central nervous system (CNS) hemorrhage. Cancer Chemother Pharmacol 71(6):1561-1565
14. Armstrong TS, Wen PY, Gilbert MR, Schiff D (2012) Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol 14(10):1203-1214
15. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963-1972
16. Schiff D, Reardon DA, Kesari S et al (2010) Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM). J Clin Oncol 28(No 15 suppl):2011
17. Batchelor TT, Mulholland P, Neyns B et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31(26):3212-3218
18. de Groot JF, Prados M, Urquart T et al (2009) A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J Clin Oncol 27(15s): Abstract 2047
19. Paschold EH, Mazieres J, Lena H et al (2012) A randomized, double-blinded, phase II study of paclitaxel/carboplatin (PC) plus CT-322 versus PC plus bevacizumab (Bev) as first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 30(No 15-suppl (May 20 Supplement)): Abstract 7584